By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Helsinn Healthcare SA 

P.O. Box 357

Pambio-Noranco    6915  Switzerland
Phone: 41-91-985-21-21 Fax: +41-91-993-21-22


SEARCH JOBS


Industry
Healthcare






Company News
Helsinn Healthcare SA,The University of Texas MD Anderson Cancer Center Enter Strategic Alliance To Improve Life Of Patients Conducting Clinical Studies In Cancer Supportive And Palliative Care 4/26/2016 6:43:19 AM
Helsinn Healthcare SA Reaches Settlement Agreement Regarding Patent Dispute On ALOXI 10/13/2015 6:48:10 AM
Zealand Pharma  (ZEAL.CO) And Helsinn Healthcare SA Announce The Advance Of Elsiglutide Into Phase IIB Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015 7:50:17 AM
Helsinn Healthcare SA And Zealand Pharma  (ZEAL.CO) Announce The Advance Of Elsiglutide Into Phase 2B Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015 7:20:15 AM
Helsinn Healthcare SA Reaches Settlement Agreement Regarding Patent Dispute On ALOXI® 1/12/2015 7:05:21 AM
Zealand Pharma and Helsinn Healthcare SA Announce Helsinn’s Decision to Advance the Development of Elsiglutide into Phase IIb for the Prevention of Chemotherapy-Induced Diarrhea 5/28/2013 9:09:30 AM
Zealand Pharma Receives Milestone Payment from Helsinn Healthcare SA 12/9/2010 11:24:11 AM
Helsinn Healthcare SA and Eisai Inc. (ESALF.PK) Extend Relationship 6/9/2010 9:35:36 AM
Helsinn Healthcare SA Announces the Acquisition of Sapphire Therapeutics, Inc. to Establish Helsinn Therapeutics (US) Inc. 1/28/2009 11:27:12 AM
Helsinn Healthcare SA Announces Partnering Agreement for ZP1846, a Novel GLP-2 Agonist from Zealand Pharma 12/11/2008 8:52:29 AM
123
//-->